Actavis Expands into New Markets; May Enter Biosimilars

摘要

Generic pharmaceuticals producer Actavis says it is expanding its presence in regions such as Japan, the Mideast, and South America. The company is also monitoring closely the biosimilars market and related activities within the sector. Actavis, which is not currently involved in the biosimilars business, is considering entering the market by establishing joint ventures or partnerships, says Stefan Sveinsson, EVP/R&D at Actavis. Actavis, meanwhile, says it is entering the Japanese generics market through a joint venture with Aska Pharmaceutical that was established earlier this year.